Iomeron

Iomeprol, the active ingredient in Iomeron, is an iodinated contrast media presented as a sterile injectable solution for intra‑arterial, intrathecal, and intravenous use. It enhances radiographic visualization during diagnostic imaging procedures such as angiography, computed tomography, and myelography.

GNH USA supplies Iomeron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides quality‑assured batches that meet EU regulatory standards and supports global procurement for imaging departments. Customers receive technical documentation, safety data sheets, and responsive regulatory assistance to ensure seamless integration into clinical workflows.

Iomeron, an iodinated contrast agent, is employed in imaging procedures that require enhanced X‑ray attenuation. - Angiography: Provides detailed vascular visualization to aid diagnosis and interventional planning. - Computed Tomography (CT) imaging: Improves soft‑tissue contrast for clearer cross‑sectional images. - Myelography: Enhances spinal canal imaging for accurate assessment of nerve root and disc pathology. - Other diagnostic imaging procedures requiring contrast: Facilitates visualization of organs and lesions where native tissue contrast is insufficient.

Iomeron may cause a range of adverse reactions following administration.

Common Side Effects: - Warmth or flushing sensation at the injection site. - Metallic taste in the mouth. - Nausea or mild vomiting. - Transient headache. - Mild urticaria or skin itching. - Temporary increase in blood pressure.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Contrast‑induced nephropathy leading to acute kidney injury. - Hypotension or cardiovascular collapse. - Arrhythmias or cardiac arrest. - Seizures or neurological disturbances. - Persistent skin rash or Stevens‑Johnson syndrome.

Before using Iomeron, clinicians should consider several safety measures. - Renal function assessment: evaluate baseline kidney function and consider hydration to reduce nephrotoxicity risk. - Allergy history: screen for prior reactions to iodinated contrast agents or iodine‑containing substances. - Thyroid disease: use caution in patients with hyperthyroidism or thyroid dysfunction. - Medication review: assess concurrent use of nephrotoxic drugs and adjust therapy as needed. - Pregnancy and lactation: weigh potential benefits against risks; use only when essential. - Store at ambient temperature: keep in original container, protect from light and moisture.

Iomeron can interact with other agents that affect renal function or iodine metabolism.

Major Interactions (Avoid): - Concurrent use of other high‑osmolar contrast agents: may increase risk of renal toxicity. - Iodine‑containing medications (e.g., amiodarone) in patients with thyroid disease: can exacerbate thyroid dysfunction. - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) combined with Iomeron may heighten renal injury risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask contrast‑induced tachycardia. - Diuretics: may alter fluid balance and affect renal clearance. - Metformin: consider temporary discontinuation in patients with impaired renal function to avoid lactic acidosis.